Adolescent Participation in HPV Vaccine Clinical Trials: Are Parents Willing?

9Citations
Citations of this article
89Readers
Mendeley users who have this article in their library.

Abstract

Approximately one-quarter of human papillomavirus (HPV) infections are acquired by adolescents, with a higher burden among racial/ethnic minorities. However, racial/ethnic minorities have been underrepresented in previous HPV vaccine trials. Ongoing and future HPV vaccine optimization trials would benefit from racially- and ethnically-diverse sample of adolescent trial participants. This study examined factors influencing parental willingness to consent to their adolescents’ participation in HPV vaccine clinical trials and tested for possible racial differences. A convenience sample of parents of adolescents (N = 256) completed a cross-sectional survey. Chi square analyses were used to assess racial differences in parental HPV vaccine awareness and intentions and willingness to consent to their child participating in an HPV vaccine clinical trial. Ordinal logistic regression was used to identify factors associated with willingness. Approximately 47% of parents were willing to allow their adolescent to participate in HPV vaccine clinical trials (30.7% African American and 48.3% Caucasian, p =.081). African Americans had lower HPV vaccine awareness (p =.006) but not lower intentions to vaccinate (p =.086). Parental willingness was positively associated with the following variables: Child’s age (p

Cite

CITATION STYLE

APA

Erves, J. C., Mayo-Gamble, T. L., Hull, P. C., Duke, L., & Miller, S. T. (2017). Adolescent Participation in HPV Vaccine Clinical Trials: Are Parents Willing? Journal of Community Health, 42(5), 894–901. https://doi.org/10.1007/s10900-017-0331-x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free